Skip to content

Rockwood Frailty Index and Survival in Hospital-at-Home Patients

Assessment of One-year Mortality Risk Using the Modified 34-item Rockwood Index

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07529470
Acronym
DOMMOR
Enrollment
2610
Registered
2026-04-14
Start date
2021-01-01
Completion date
2024-12-31
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty, Home Care Services, Hospital-Based, Mortality, Palliative Care

Keywords

Hospital at home, Frailty, Survival, Complex Chronic Patients, Rockwood Index

Brief summary

Frailty is a key determinant of prognosis in older adults with complex chronic conditions and in palliative care settings. The Rockwood Frailty Index (RFI), based on the accumulation of health deficits, has demonstrated prognostic value across multiple clinical contexts. This study evaluates the association between the RFI and overall survival in complex chronic and palliative patients (oncologic and non-oncologic) treated in a Hospital-at-Home (HaH) unit.

Detailed description

This retrospective longitudinal observational cohort study included patients aged 65 years or older admitted to a Hospital-at-Home (HaH) unit between January 1, 2021 and December 31, 2024. All patients had a recorded modified Rockwood Frailty Index (RFI) at admission and were subsequently followed through a structured case-management program led by nurse case managers via scheduled telephone follow-up. Patients were classified into three clinical groups: complex chronic patients, non-oncologic palliative patients, and oncologic palliative patients. Non-oncologic palliative status was defined by an RFI ≥0.53, while complex chronic patients had an RFI \>0.37 and \<0.53. Oncologic palliative patients were classified based on referral from Oncology services regardless of frailty level. The primary outcome was overall survival, defined as time from discharge from the HaH unit to death from any cause. Survival analyses were conducted using Kaplan-Meier curves and multivariate Cox proportional hazards regression models adjusted for relevant demographic, clinical, and laboratory covariates.

Interventions

OTHERPatients identified and followed in this cohort received scheduled supportive telephone calls every two weeks if classified in the oncologic palliative care group, and once monthly in the case of comp

Patients in this cohort received scheduled supportive telephone calls every two weeks if classified under palliative care (oncologic or chronic conditions), and once monthly if classified as chronic non-palliative patients.

Sponsors

Instituto de Investigacion Sanitaria La Fe
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥65 years * Admission to the Hospital-at-Home unit during the study period * Recorded modified Rockwood Frailty Index at admission * Participation in the post-discharge case management follow-up program

Exclusion criteria

* Incomplete data for frailty index calculation * Immediate loss to follow-up after discharge

Design outcomes

Primary

MeasureTime frameDescription
Overall Survival1 yearTime from discharge from the Hospital-at-Home unit to death from any cause.

Secondary

MeasureTime frameDescription
Comparative prognostic performance of the Rockwood Frailty Index versus Charlson Comorbidity Index1 yearComparison of the prognostic performance of the Rockwood Frailty Index and the Charlson Comorbidity Index for predicting overall survival. Measure: Hazard Ratios (HRs) for overall survival for each index. Unit of Measure: Hazard ratio Measurement Tool / Method: Rockwood Frailty Index; Charlson Comorbidity Index; Cox proportional hazards regression models.
Association between age and overall survival1 yearOverall survival according to age at baseline. Measure: Hazard Ratio (HR) for overall survival per year increase in age Unit of Measure: Hazard ratio Measurement Tool / Method: Cox proportional hazards regression model
Association between sex and overall survival1 yearDescription: Overall survival according to sex at baseline. Measure: Hazard Ratio (HR) for overall survival comparing sex categories. Unit of Measure: Hazard ratio Measurement Tool / Method: Cox proportional hazards regression model
Association between overall survival and clinical variables (Charlson Comorbidity Index)1 yearOverall survival according to Charlson Comorbidity Index at baseline. Measure: Hazard Ratio (HR) for overall survival per point increase in Charlson Comorbidity Index. Unit of Measure: Hazard ratio Measurement Tool / Method: Charlson Comorbidity Index; Cox proportional hazards regression model
Association between overall survival and clinical variables (Barthel Index)1 yearDescription: Overall survival according to the Barthel Index at baseline. Measure: Hazard Ratio (HR) for overall survival per point increase in Barthel Index. Unit of Measure: Hazard ratio Measurement Tool / Method: Barthel Index; Cox proportional hazards regression model
Association between overall survival and laboratory parameters (C-reactive protein)1 yearOverall survival according to C-reactive protein levels at baseline. Measure: Hazard Ratio (HR) for overall survival per unit increase in C-reactive protein. Unit of Measure: Hazard ratio Measurement Tool / Method: Serum C-reactive protein concentration (mg/L); Cox proportional hazards regression model
Association between overall survival and laboratory parameters (albumin)1 yearDescription: Overall survival according to serum albumin levels at baseline. Measure: Hazard Ratio (HR) for overall survival per unit increase in serum albumin. Unit of Measure: Hazard ratio Measurement Tool / Method: Serum albumin concentration (g/dL); Cox proportional hazards regression model

Countries

Spain

Contacts

PRINCIPAL_INVESTIGATORVicente Ruiz Garcia, MD, PhD

Hospital at Home Unit - Hospital UiP La Fe Valencia Avda Fernando Abril Martorell 106 Torre B Planta 1 Valencia 26206 (SPAIN)

STUDY_CHAIRElisa Soriano Melchor, MD, PhD

Hospital at Home Unit - Hospital UiP La Fe Valencia Avda Fernando Abril Martorell 106 Torre B Planta 1 Valencia 26206 (SPAIN)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026